Type 1 diabetes is the most common severe chronic autoimmune disease worldwide, and the incidence of the disease is rising rapidly. It causes the immune system to mistake cells in the pancreas for harmful cells and attack them. When these cells are damaged the pancreas is unable to produce insulin, which plays an essential part in transferring glucose out of the bloodstream and into cells to be converted into energy.
The management of type 1 diabetes usually involves measuring the amount of glucose in the blood and injecting artificial insulin to make up for the insulin the pancreas is not producing.
Type 1 diabetes is known to be a genetically complex disease – there is no single gene that causes the disease, but rather dozens of genes that increase the risk of developing it. However, genetic studies have identified variants of one particular gene – known as interleukin-2, or IL2 – that seems to have a prominent role. IL-2 is important in helping regulate the immune system.
Now, for the first time, researchers at Addenbrooke’s Hospital and the Wellcome Trust-funded Cambridge Institute for Medical Research (CIMR) at the University of Cambridge are investigating whether interleukin-2 in the form of a drug called aldesleukin (Proleukin) could be used to halt the damage to the pancreas in people with newly diagnosed type 1 diabetes and, if so, what dose of the drug is required for the best results.
Professor John Todd FRS from the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, University of Cambridge, says: “Studying the genetics of type 1 diabetes has proved essential to help us understand what is happening in the disease at a cellular and molecular level. This type of research takes time, but we are now beginning to test its true potential for improving the lives of patients in our innovative translational medicine programme.”
The clinical trial is being led by Dr Frank Waldron-Lynch from the University of Cambridge and is coordinated by the Cambridge Clinical Trials Unit at Addenbrooke’s Hospital. Dr Waldron-Lynch adds: “Type 1 diabetes is a potentially very serious disease that requires lifelong treatment and regular insulin injections throughout the day. Our aim is to use aldesleukin to rebalance the immune system so that patients can significantly reduce the number of insulin injections needed to just once or twice a week by slowing the progression of the disease.”
The first two participants have been enrolled onto the trial and have received treatment. At the moment, the trial is to help gauge the necessary dose in adults, beginning with very low doses; ultimately, the researchers hope to be able to use this treatment in children.
Dr Waldron-Lynch says that so far the results have been very positive, even on a very low dose, with no detectable side-effects. However, they are looking to recruit more participants to the ‘adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes’ (DILT1D) to help them determine with confidence whether the drug is effective and at what dose.
The trial is being funded by the Wellcome Trust and JDRF, the type 1 diabetes charity, combined with funding from the National Institute of Health Research, a UK government body that coordinates and funds research for the NHS.
Dr Michael Dunn, Head of Molecular and Physiological Sciences at the Wellcome Trust, says: “We have invested heavily in genetics over the past few decades to understand the biological causes of diseases. At the same time as showing us how complex diseases are, it has also provided tantalising clues as to how they may be treated.
“This is the first time that ‘immunotherapy’ – in other words, trying to rebalance the immune system – has been trialled in the UK as a way of tackling type 1 diabetes, and it would not have been possible without the strong foundation of genetics and immunology research that underpins it.”
Karen Addington, Chief Executive of JDRF, said: “Across the UK, hundreds of thousands of people with type 1 diabetes suffer the disruption of insulin injections several times every day. These injections interrupt their work, their play, their time with family and sometimes their sleep. We must continue to support crucial research such as this which focuses on better treatment for those living with the condition.”
Professor Gillian Griffiths FRS, Director of the CIMR at the University of Cambridge, says: “I am delighted that the Diabetes and Inflammation Laboratory are rolling out this important translational medicine programme based on the cutting-edge basic biomedical research which they have carried out within the Cambridge Institute for Medical Research.”
Image: A person with diabetes testing their blood glucose level. Credit: Wellcome Library, London.
To register interest to take part in the trial, please contact Dr Frank Waldron-Lynch and team on 01233 762327, email [email protected], or text DILT1D to 82727. Participants should be aged between 18 and 50 and have been diagnosed with type 1 diabetes in the past two years. Further details are available from the DILT1D trial website.
Senior Media Officer
The Wellcome Trust
T +44 (0)20 7611 7262
E [email protected]
Notes for editors
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
JDRF exists to cure, treat and prevent type 1 diabetes, and is the world’s leading charitable funder of type 1 diabetes research. At a global level JDRF volunteers and staff have been responsible for raising over £1 billion to support type 1 diabetes research since the charity’s inception.
About the National Institute for Health Research
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world.
About the Cambridge Clinical Trials Unit
The Cambridge Clinical Trials Unit is a UKCRC registered CTU. The CCTU was established in July 2010 and is hosted at Cambridge University Hospitals NHS Foundation Trust (CUH) as part of the infrastructure of the Cambridge Comprehensive Biomedical Research.